Entyvio
(Vedolizumab)ApprovedMonoclonal antibody
TakedaVedolizumab is used to treat inflammatory bowel diseases like Crohn's disease and ulcerative colitis by reducing inflammation in the digestive tract. It helps reduce symptoms and allows the intestines to heal.[2] Entyvio is currently approved and in use across 11 indications[4].[1]
Entyvio is one of 190 small molecule programs targeting Ulcerative Colitis. It is currently in Approved.
11
Indications
118
Total Trials
35
Active Trials
189
Competitors
2
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 11 indications
Competition
Competitive Landscape
163 competitors in Acute Lymphoblastic Leukemia
#DrugCompanyPhaseTrials
1Oncovin
Eli LillyPhase 3
Adriamycin
PfizerPhase 3
Oncaspar
SServier
Phase 3
Wellcovorin
EEastern Cooperative Oncology Group
Phase 3
Elspar
DDutch Childhood Oncology Group
Phase 3
Medrol
PfizerPhase 3
Cellcept
RochePhase 3
Entyvio
TakedaApproved
Arranon
NovartisPhase 3
Mesnex
BBaxter Healthcare Corporation
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Ulcerative Colitis46 trials
Show 43 more trials
The Association Between Interleukin-7 Receptor Gene Polymorphism and the Risk of Ulcerative Colitis
Completed·SSecond Affiliated Hospital of Wenzhou Medical University·Phase 4·NCT07398586·898 enrolled
Crohn's Disease13 trials
Show 10 more trials
Value of Pharmacokinetic Assays in the Prediction of Induction and Maintenance Therapeutic Response in Crohn's Disease
Terminated·—·Phase 4·NCT02768532·47 enrolled
Moderate to Severe Crohn's Disease4 trials
Colitis4 trials
Inflammatory Bowel Disease4 trials
34 more indications
Tics3 trials
Effectiveness3 trials
Intravenous2 trials
Pouchitis2 trials
Inflamatory Bowel Disease2 trials
Crohn's Disease (CD)2 trials
Pilot Study2 trials
Immunogenicity1 trial
Biological Therapy1 trial
Efficacy of Vedolizumab in Crohn's Disease Patients Naive to Biological Therapy
Unknown status·—··NCT04362735·100 enrolled
Infection1 trial
Biologics1 trial
Prediction Model for Response to Biologics and Small Molecular Agent for UC
Recruiting·—··NCT05186623·300 enrolled
Treatment1 trial
Immune Effects of Vedolizumab With or Without Anti-TNF Pre-treatment in T1D
Completed·—·Phase 1·NCT05281614·20 enrolled
Melanoma1 trial
Immune Response1 trial
Gastrointestinal1 trial
Non-small Cell Lung Cancer (NSCLC)1 trial
IrAE1 trial
Ulcerative Colitis (UC)1 trial
Cutaneous Melanoma1 trial
Acute Lymphoblastic Leukemia1 trial
Unspecified5 trials
Subcutaneous Interval Lengthening of Vedolizumab for Economic Research
Recruiting·—·Phase 4·NCT06584162·40 enrolled
Regulatory
FDA Approval Timeline[5]
May 20, 2014
ENTYVIO
BLA BLA125476
Sep 27, 2023
ENTYVIO
BLA BLA761133
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Entyvio drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Vedolizumab. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]